logo
Plus   Neg
Share
Email

Genentech: Phase III IMspire150 Study Of Tecentriq Meets Primary Goal

Genentech, a member of Swiss drug maker Roche Group (RHHBY), announced Friday that the Phase III IMspire150 study of Tecentriq Plus Cotellic and Zelboraf in people with previously untreated BRAF V600 mutation-positive advanced melanoma met its primary endpoint of progression-free survival.

The study showed adding Tecentriq (atezolizumab) to Cotellic (cobimetinib) and Zelboraf (vemurafenib) helped to reduce the risk of disease worsening or death, compared to placebo plus Cotellic and Zelboraf.

The company noted that a significant and clinically meaningful improvement in PFS was demonstrated in the study. The safety profile observed in IMspire150 was consistent with the known safety profiles of the individual medicines.

The company will present the results from the study at an upcoming medical meeting and discuss with health authorities, including the U.S. Food and Drug Administration and European
Medicines Agency.

Genentech said it has an extensive clinical trial development program for Tecentriq, with more than 50 ongoing studies, including multiple Phase III studies across lung, kidney, skin, breast, colorectal, prostate, ovarian, bladder, blood, liver and head and neck cancers.

Studies are evaluating Tecentriq alone and in combination with other medicines.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration has granted accelerated approval to Tazverik for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Epithelioid sarcoma is a rare sub-type of soft... STIHL recalls about 16,400 STIHL RE 90 pressure washers due to injury hazard. According to the company, the recalled pressure washer nozzle can disconnect from the spray wand when under pressure during use, posing an injury hazard. STIHL said it received seven reports of the nozzle detaching from... CVS Health Corp. launched 13 new HealthHUB locations in CVS Pharmacy stores across Philadelphia and South New Jersey. The healthcare company said it developed the HealthHUB store format to help people manage chronic conditions more conveniently and affordably. The store also features health and wellness products, clinical services and expertise.
Follow RTT
>